No Data
In 2024, Moutai's total revenue is 170.9 billion, with a net income increase of 15.4% year-on-year, and the dividend amount has reached a new high | Earnings Reports insights.
In 2024, Moutai's total revenue reached 170.9 billion, with a year-on-year increase of 15.7%. The revenue from Moutai liquor accounts for over 85%, while revenue from its series of liquors surpassed 20 billion. The annual net income is 86.2 billion, representing a year-on-year growth of 15.4%, with a proposal to distribute a cash dividend of 276.24 yuan (after tax) for every 10 shares.
New executives appointed! Jiangsu Hengrui Pharmaceuticals appoints a new president, aiming to strengthen internationalization?|Quick announcement summary
① Feng Ji, who has worked for AstraZeneca for many years, has officially been appointed as the President and Chief Operating Officer of Jiangsu Hengrui Pharmaceuticals. ② According to industry insiders, the current executive team at Hengrui remains stable, with no significant changes in the roles of other major executives. ③ Industry insiders believe that Jiangsu Hengrui Pharmaceuticals values Feng Ji's experience in multinational pharmaceutical companies.
The entire pharmaceutical sector has surged sharply; what happened?
On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.
The "wind" has reached the pharmaceutical stocks, and the Sector is experiencing a surge in limit-up prices! What are the Bullish catalysts?
Catalysts from news, warming performance, and the advantages of valuation may become the main factors boosting the rise of pharmaceutical stocks.
In 2024, Jiangsu Hengrui Pharmaceuticals achieved record high revenue and net profit, with explosive growth in Innovative Drugs and research and development investment accounting for nearly 30% of revenue | Earnings Reports insights.
Net income is 6.337 billion yuan, a sharp increase of 47.28% year-on-year. Innovative Drugs sales reached 13.892 billion yuan, a year-on-year growth of 30.60%, accounting for nearly 50% of total revenue, becoming the core engine for performance growth.
Another 13 companies added this week! Midea Group Co., Ltd and several other stocks have disclosed plans for shareholding and repurchase loan plans. A list of related A-shares is provided.
① According to incomplete Statistics, as of the time of publication, 13 listed companies disclosed information related to repurchase Shareholding and refinancing this week (attached table); ② Midea Group Co., Ltd received the highest special loan amount, with the loan amount not exceeding 9 billion yuan.